NCT06238024View on ClinicalTrials.gov

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

June 25, 2024

Study Completion Date

September 22, 2024

Conditions

Interleukin-6Ischemic StrokeEndovascular Treatment

Interventions

DRUG

Tocilizumab

Single dose intravenous application

DRUG

NaCl 0.9% 100ml

Single dose intravenous application

Trial Locations (1)

Unknown

Suzhou Municipal Hospital of Anhui Province, Suzhou

All Listed Sponsors

collaborator

Xuanwu Hospital, Beijing

OTHER

lead

Suzhou Municipal Hospital of Anhui Province

OTHER

NCT06238024 - Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment | Biotech Hunter | Biotech Hunter